Enzalutamide
Brand name: Xtandi
Rank #15 of 500 drugs by total cost
$985.0M
Total Cost
72,710
Total Claims
$985.0M
Total Cost
2,280
Prescribers
$14K
Cost per Claim
3,604
Beneficiaries
73,470
30-Day Fills
$432K
Avg Cost/Provider
32
Avg Claims/Provider
About Enzalutamide
Enzalutamide (sold as Xtandi) was prescribed 72,710 times by 2,280 Medicare Part D providers in 2023, costing the program $985.0M. At $14K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 12 | Sacubitril/Valsartan (Entresto) | $1.30B | 1,220,812 |
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology